natgillin/translations-raw huggingface dataset:
The dsRNA of any one of claims 1 to 5, wherein said dsRNA comprises at least one modified nucleotide, wherein preferably at least one of said modified nucleotides is chosen from the group of: a 2'-O-methyl modified nucleotide, a nucleotide comprising a 5'-phosphorothioate group, a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group, a 2'-deoxy-2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2'-amino-modified nucleotide, 2'-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide. 
dsRNA prema bilo kojem od zahtjeva 1 do 7, naznačena time da navedena dsRNA obuhvaća barem jedan modificirani nukleotid, pri čemu se poželjno najmanje jedan od navedenih modificiranih nukleotida bira iz skupine koju čine: 2'-O-metil modificirani nukleotid, nukleotid koji sadrži 5'-fosforotioatnu skupinu, terminalni nukleotid povezan s derivatom kolesterila ili bisdecilamidnom skupinom dodekanske kiseline, 2'-deoksi-2'-fluoro modificirani nukleotid, 2'-deoksi-modificirani nukleotid, zaključani nukleotid, abazični nukleotid, 2'-amino modificirani nukleotid, 2'-alkil modificirani nukleotid, morfolino nukleotid, fosforamidat, te ne-prirodna baza koja sadrži nukleotid.
A method of inhibiting TTR expression in a cell, the method comprising: 
Postupak inhibiranja TTR ekspresije u stanici, naznačen time da postupak sadrži:
maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of a TTR gene, thereby inhibiting expression of the TTR gene in the cell; 
održavanje stanice proizvedene u koraku (a) tijekom vremena dovoljnog za dobivanje degradacije mRNA transkripta TTR gena, čime se inhibira ekspresija TTR gena u stanici;
the human has a liver disorder wherein said transthyretin amyloidosis is preferably selected from familial amyloidotic polyneuropathy (FAP), familial amyloidotic cardiomyopathy (FAC), leptomeningeal/CNS amyloidosis, senile systemic amyloidosis (SSA) and senile cardiac amyloidosis (SCA). 
čovjek ima poremećaj jetre pri čemu je navedena transtiretinska amiloidoza poželjno odabrana od nasljedne amiloidne polineuropatije (FAP), nasljedne amiloidne kardiomiopatije (FAC), leptomeningealne/CNS amiloidoze, senilne sistemske amiloidoze (SSA) i senilne kardijalne amiloidoze (SCA).
The dsRNA for use of claim 14 or 15, wherein the human is additionally receiving a therapeutic method for treating a TTR amyloidosis, the therapeutic method selected from the group consisting of diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, dialysis, and a liver transplant. 
dsRNA za uporabu prema zahtjevu 14 ili 15, naznačena time da čovjek dodatno prima terapeutski postupak za liječenje TTR amiloidoze, terapeutski postupak je odabran iz skupine koja se sastoji od diuretika, inhibitora enzima koji pretvaraju angiotenzin, blokatora angiotenzinskih receptora, dijalize i transplantacije jetre.
An oligosaccharide-protein conjugate, comprising (1) a protein, (2) an oligosaccharide, and (3) an oxime group connecting the protein and the oligosaccharide wherein the oligosaccharide is an oligosaccharide of Formula VI: 
Konjugat oligosaharid-protein, koji sadrži (1) protein, (2) oligosaharid, te (3) oksimsku skupinu koja spaja protein i oligosaharid naznačen time da oligosaharid je oligosaharid s Formulom VI: [image]
providing a protein having at least one carbonyl group; and 
osiguravanje proteina koji ima barem jednu karbonilnu skupinu; i
reacting the aminooxy group of the oligosaccharide with the at least one carbonyl group of the protein, thereby coupling the oligosaccharide to the protein, wherein the oligosaccharide is an oligosaccharide of Formula IV: wherein m and p are independently chosen from integers ranging from 1 to 10. 
reakciju aminooksi skupine oligosaharida s barem jednom karbonilnom skupinom proteina, te se tako spaja oligosaharid na protein, pri čemu oligosaharid je oligosaharid s Formulom IV: [image] pri čemu su m i p neovisno odabrani od cijelih brojeva u rasponu od 1 do 10.
A method as claimed in claim 5 wherein the protein is a glycoprotein and the at least one carbonyl group is obtained by oxidation of the glycoprotein with periodate. 
Postupak prema zahtjevu 11 naznačen time da protein je glikoprotein i barem jedna karbonilna skupina se dobiva oksidacijom glikoproteina s perjodatom.
providing an oligosaccharide comprising a first reactive group, wherein the oligosaccharide is or 
osiguravanje oligosaharida koji sadrži prvu reaktivnu skupinu, pri čemu oligosaharid je [image] ili [image]
providing an aminooxy compound comprising a second reactive group, wherein the aminooxy compound is chosen from compounds of Formula II: wherein Y is the second reactive group, Z is chosen from alkyl, alkenyl, alkynyl, heteroaryl, aryl, and heterocyclyl, and P is chosen from amino protecting groups; and 
osiguravanje aminooksi spoja koji sadrži drugu reaktivnu skupinu, pri čemu je aminooksi spoj odabran od spojeva s Formulom II: [image] pri čemu Y je druga reaktivna skupina, Z je odabran od alkila, alkenila, alkinila, heteroarila, arila, i heterociklila, i P je odabran od amino zaštitnih skupina; i
reacting the first reactive group of the oligosaccharide with the second reactive group of the aminooxy compound, thereby preparing the oligosaccharide comprising an aminooxy group. 
reakciju prve reaktivne skupine oligosaharida s drugom reaktivnom skupinom aminooksi spoja, te se tako priprema oligosaharid koji sadrži aminooksi skupinu.
An oligosaccharide comprising an aminooxy group prepared by a method comprising the steps of claim 12 wherein the aminooxy compound is chosen from compounds of Formula III: wherein n is chosen from integers ranging from 1 to 10. 
Oligosaharid koji sadrži aminooksi skupinu pripremljenu pomoću postupka koji sadrži korake prema zahtjevu 16 naznačen time da je aminooksi spoj odabran od spojeva s Formulom III: [image] pri čemu je n odabran od cijelih brojeva u rasponu od 1 do 10.
is H, or R4 and R5 and the common carbon atom to which they are attatched, join to form an endocyclic -C(O)- group; 
je H, ili R4 i R5 i zajednički atom ugljika za koji su vezani, spajaju se tako da formiraju endocikličnu -C(O)- grupu;
is C1-C6 alkyl, which is optionally substituted with a group selected from phenyl, C3-C7 cycloalkyl, 5 or 6-membered monocyclic heteroaryl and -O-(C1-C6 alkyl), wherein said phenyl group and said 5 or 6-membered monocyclic heteroaryl group can each be optionally and independently substituted with up to two groups, each independently selected from C1-C6 alkyl, halo and -O-(C1-C6 alkyl); 
je C1-C6 alkil, koji je izborno supstituiran s grupom izabranom od fenila, C3-C7 cikloalkila, 5 ili 6-članog monocikličnog heteroarila i -O-(C1-C6 alkila), pri čemu navedena fenil grupa i navedena 5 ili 6-člana monociklična heteroaril grupa svaka mogu biti izborno i nezavisno supstituirane s do dvije grupe, svaka nezavisno izabrana od C1-C6 alkila, halo i -O-(C1-C6 alkila);
The compound of any of claims 1-6, wherein R8 is benzyl, wherein the phenyl moiety of said benzyl group can be optionally and independently substituted with up to 3 groups, each independently selected from F, Cl, and methyl. 
Spoj prema bilo kojem od patentnih zahtjeva 1-6, naznačen time što je R8 benzil, pri čemu fenil grupa navedene benzil grupe može biti izborno i nezavisno supstituirana s do 3 grupe, svaka nezavisno izabrana od F, Cl i metila.
The compound of any of claims 1-7, wherein R1 is C1-C6 alkyl, which is optionally substituted with a group selected from phenyl, 5 or 6-membered monocyclic heteroaryl, C3-C7 cycloalkyl and methoxy, wherein said phenyl group and said 5 or 6-membered monocyclic heteroaryl group can each be optionally and independently substituted with up to two groups, each independently selected from methoxy, C1-C6 alkyl and fluoro. 
Spoj prema bilo kojem od patentnih zahtjeva 1-7, naznačen time što R1 je C1-C6 alkil, koji je izborno supstituiran grupom izabranom od fenila, 5 ili 6-članog monocikličnog heteroarila, C3-C7 cikloalkila i metoksi, pri čemu navedena fenil grupa i navedena 5 ili 6-člana monociklična heteroaril grupa svaka mogu biti izborno i nezavisno supstituirane s do dvije grupe, svaka nezavisno izabrana od metoksi, C1-C6 alkila i fluoro.
A pharmaceutical composition comprising an effective amount of a compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija koja sadrži efikasnu količinu spojeva prema bilo kojem od patentnih zahtjeva 1 do 9, ili njegove farmaceutski prihvatljive soli i farmaceutski prihvatljiv nosač.
A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, for use in the inhibition of HIV integrase, for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis, or delay in the onset or progression of AIDS in a subject in need thereof. 
Spoj prema bilo kojem od patentnih zahtjeva 1 do 9, ili njegova farmaceutski prihvatljiva sol, za uporabu u inhibiciji HIV integraze, za liječenje ili profilaksu infekcije HIV-om, ili za liječenje, profilaksu ili odlaganje početka ili napredovanja SIDA-e kod subjekta kod kojeg postoji potreba za tim.
is not a mono substituted hydroxymethyl. 
nije mono supstituiran hidroksimetil.
The compound according to claim 1 having the formula Ib-1b': and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein D, L2, Ar1, Ar2, R, R1, R2, R3, R3' and R4 are as defined in claim 1. 
Spoj sukladno patentnom zahtjevu 1 da ima formulu Ib-1b’: [image] i njegove farmaceutski prihvatljive soli i solvati, gdje D, L2, Ar1, Ar2, R, R1, R2, R3, R3’ i R4 su definirani kao u patentnom zahtjevu 1.
The compound according to claim 2 having the formula Ib-1d: and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein Ar1, Ar2, R1, R2 and R are as defined in claim 1; 
Spoj sukladno patentnom zahtjevu 2 da ima formulu Ib-1d: [image] i njegove farmaceutski prihvatljive soli i solvati, gdje Ar1, Ar2, R1, R2 i R su definirani kao u patentnom zahtjevu 1;
The compound according to claim 3 having the formula Ib-1e: and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein Ar2, R1, R2 and R are as defined in claim 1; 
Spoj sukladno patentnom zahtjevu 3 koje ima formulu Ib-1e: [image] i njegove farmaceutski prihvatljive soli i solvati, gdje Ar2, R1, R2 i R su definirani kao u patentnom zahtjevu 1;
is selected from the group of heteroaryl moieties consisting of: wherein the arrow marks the attachment point to the phenyl ring; 
je odabran iz skupine heteroaril skupina koja se sastoji od: [image] pri čemu strelica označava točku vezivanja na fenilni prsten;
The compound according to claim 1 having the formula Ic-1b': and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein D, L2, Ar1, Ar2, R, R1, R2, R3, R3' and R4 are as defined in claim 1. 
Spoj sukladno patentnom zahtjevu 1 koje ima formulu Ic-1b’: [image] i njegove farmaceutski prihvatljive soli i solvati, gdje D, L2, Ar1, Ar2, R, R1, R2, R3, R3’ i R4 su definirani kao u patentnom zahtjevu 1.
The compound according to claim 1 having the formula Id-1b': and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein D, L2, Ar1, Ar2, R, R1, R2, R3, R3' and R4 are as defined in claim 1. 
Spoj sukladno patentnom zahtjevu 1 koje ima formulu Id-1b’: [image] i njegove farmaceutski prihvatljive soli i solvati, gdje D, L2, Ar1, Ar2, R, R1, R2, R3, R3’ i R4 su definirani kao u patentnom zahtjevu 1.
The compound according to claim 1 having the formula Ie-1b': and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein D, L2, Ar1, Ar2, R, R1, R2, R3, R3' and R4 are as defined in claim 1. 
Spoj sukladno patentnom zahtjevu 1 koje ima formulu Ie-1b’: [image] i njegove farmaceutski prihvatljive soli i solvati, gdje D, L2, Ar1, Ar2, R, R1, R2, R3, R3’ i R4 su definirani kao u patentnom zahtjevu 1.
The compound according to claim 1 selected from the group consisting of: 
Spoj sukladno patentnom zahtjevu 1 odabrano iz skupine sastavljene od:
A compound according to any of claims 1 to 20 or a pharmaceutically acceptable salt, solvate or prodrug thereof for use in the treatment and/or prevention of type II diabetes, obesity, dyslipidemia such as mixed or diabetic dyslipidemia, hypercholesterolemia, low HDL cholesterol, high LDL cholesterol, hyperlipidemia, hypertriglyceridemia, hypoglycemia, hyperglycemia, glucose intolerance, insulin resistance, hyperinsulinemia, hypertension, hyperlipoproteinemia, metabolic syndrome, syndrome X, thrombotic disorders, cardiovascular disease, atherosclerosis and its sequelae including angina, claudication, heart attack, stroke and others, kidney diseases, ketoacidosis, nephropathy, diabetic neuropathy, diabetic retinopathy, nonalcoholic fatty liver diseases such as steatosis or nonalcoholic steatohepatitis (NASH). 
Spoj sukladno bilo kojem od patentnih zahtjeva 1 do 20 ili njegova farmaceutski prihvatljiva sol ili solvat za liječenje i/ili prevenciji dijabetesa tipa II, pretilosti, dislipidemije kao što je miješana ili dijabetička dislipidemija, hiperkolesterolemije, niskog HDL kolesterola, visokog LDL kolesterola, hiperlipidemije, hipertrigliceridemije, hipoglikemije, hiperglikemije, intolerancije glukoze, inzulinske rezistencije, hiperinsulinemije, hipertenzije, hiperlipoproteinemije, metaboličkog sindroma, sindroma X, trombotičkih poremećaja, kardiovaskularne bolesti, ateroskleroze i njenih sekvela uključujući anginu, klaudikaciju, srčani udar, moždani udar i druge, bolesti bubrega, ketoacidoze, nefropatije, dijabetičke neuropatije, dijabetičke retinopatije, nealkoholnih bolesti masne jetre kao što je steatoza ili nealkoholni steatohepatitis (NASH).
is a single bond; 
je jednostruka veza;
which consists of: 
koji se sastoji od:
the coupling of a compound of formula A wherein 
povezivanja spoja formule A [image] gde
R" is Cl or OL wherein L is a carboxylic acid activating group, followed by 
R" je Cl ili OL gdje L je skupina koja aktivira karbonsku kiselinu, nakon čega slijedi
step b) being optionally followed by conversion of a compound of formula Ib-1b' to a pharmaceutically acceptable salt, solvate or prodrug thereof. 
korak b) prema potrebi slijedi pretvaranje spoja formule Ib-1b’ u njegovu farmaceutski prihvatljivu sol ili solvat.
the coupling of a compound of formula C wherein: 
povezivanja spoja formule C [image] gdje:
step b) being optionally followed by conversion of a compound of formula Ib-1b' to a pharmaceutically acceptable salt, solvate or prodrug thereof. 
korak b) prema potrebi slijedi pretvaranjem spoja formule Ib-1b’ u njegovu farmaceutski prihvatljivu sol ili solvat.
A process for the preparation of a compound of the formula Ib-1h" according to claim 12 wherein 
Postupak za pripremu spoja formule Ib-1h" sukladno patentnom zahtjevu 12 [image] gdje
which consists of: 
[image] koja se sastoji od:
an alkaline or acidic treatment, a hydrolysis, a hydrogenolysis or a treatment with fluoride of the ester intermediate obtained in step a); 
alkalni ili kiseli tretman, hidroliza, hidrogenoliza ili tretman s fluoridom estreskog međuprodukta dobivenog u koraku a);
step b) being optionally followed by conversion of a compound of formula Ib-1h" to a pharmaceutically acceptable salt, solvate or prodrug thereof. 
korak b) po izboru slijedi pretvaranje spoja formule Ib-1h" u njegovu farmaceutski prihvatljivu sol ili solvat.
The pharmaceutical composition of any one of claims 1 to 4, wherein the pharmaceutical composition has a pH of from 4 to 6. 
Farmaceutska kompozicija patentnog zahtjeva 3 ili patentnog zahtjeva 4, gdje farmaceutska kompozicija ima pH od oko 4 do oko 6.
The pharmaceutical composition of any one of claims 1 to 5, wherein the pharmaceutical composition has a pH of from 4 to 5. 
Farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 3-5, gdje farmaceutska kompozicija ima pH od oko 4 do oko 5.
The pharmaceutical composition of any one of claims 1 to 6, wherein the pharmaceutical composition has a pH of about 4. 
Farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 3-6, gdje farmaceutska kompozicija ima pH od oko 4.
The gaming and/or entertainment device according claim 1, wherein the touch panel has a curvature radius in the range from 0.5 m to 3 m. 
Uređaj za igranje i/ili zabavu sukladno jednom od prethodnih zahtjeva, pri čemu dodirna ploča (25) ima polumjer zakrivljenosti u rasponu od 0,5m do 3m, a naročito od 0,75m do 1,5m.
A method of inhibiting TTR expression in a mammalian cell, the method comprising: (a) contacting the cell with the pharmaceutical composition of claim 1 and (b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of a TTR gene, thereby inhibiting expression of the TTR gene in the cell. 
Postupak inhibiranja TTR ekspresije u stanici, naznačen time da postupak sadrži: dovođenje u kontakt stanice s dsRNA prema bilo kojem od zahtjeva 1 do 11; i održavanje stanice proizvedene u koraku (a) tijekom vremena dovoljnog za dobivanje degradacije mRNA transkripta TTR gena, čime se inhibira ekspresija TTR gena u stanici;
a nucleotide sequence encoding a carrier protein, wherein said carrier protein comprises at least one inserted consensus sequence D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; and 
nukleotidni slijed koji kodira proteinski nosač, gdje navedeni proteinski nosač sadrži aminokiselinski konsenzusni slijed D/E-X-N-Z-S/T, gdje X i Z mogu biti bilo koja prirodna aminokiselina osim prolina; i
is selected from the group consisting of: D-4 c1, 
je odabran iz skupine heteroaril skupina koja se sastoji od:
is selected from the group consisting of: 
je jednostruka veza; koji se sastoji od:
is selected from the group consisting of: 
[image] koja se sastoji od:
Process for the recovery of enthalpy and metals from Li-ion batteries on a copper smelter, comprising the steps of: 
Postupak oporabe entalpije i metala iz litij-ionskih baterija u talionici bakra koji se sastoji od sljedećih koraka:
adding heating and reducing agents; 
dodavanje sredstava za zagrijavanje i redukcijskih sredstava;
Process according to claims 1 or 2, wherein the major part of the Li-ion batteries contain 3 wt.% of Co or less. 
Postupak u skladu sa zahtjevom 1. Ili 2. gdje veći dio litij-ionskih baterija sadrži maseni udio od 3% kobalta ili manje.
A first agent and a second agent, wherein said first agent is an antigen-binding protein that binds to HER-3, and comprises: a heavy chain amino acid sequence that comprises a CDRH1 as shown in SEQ ID NO: 256; a CDRH2 as shown in SEQ ID NO: 282; and a CDRH3 as shown in SEQ ID NO: 315; and a light chain amino acid sequence that comprises a CDRL1 as shown SEQ ID NO: 340; a CDRL2 as shown in SEQ ID NO: 344; and a CDRL3 as shown in SEQ ID NO: 387, and wherein the second agent is Erlotinib for use in the treatment or prevention of lung cancer. 
Prvo sredstvo i drugo sredstvo za upotrebu u liječenju ili prevenciji hiperproliferativne bolesti povezane s HER-3, naznačeno time što je navedena hiperproliferativna bolest karcinom koji ima ekspresiju ili prekomjernu ekspresiju HER-3, naznačeno time što je navedeno drugo sredstvo trastuzumab, i naznačeno time što navedeno prvo sredstvo predstavlja antigen-vezujući protein koji se veže za HER-3, i sadrži: aminokiselinsku sekvencu teškog lanca koja sadrži CDRH1 kao što je prikazano u sekvenci SEQ ID NO: 256; CDRH2 kao što je prikazano u sekvenci SEQ ID NO: 282; i CDRH3 kao što je prikazano u sekvenci SEQ ID NO: 315; i aminokiselinsku sekvencu lakog lanca koja sadrži CDRL1 kao što je prikazano u sekvenci SEQ ID NO: 340; CDRL2 kao što je prikazano u sekvenci SEQ ID NO: 344; i CDRL3 kao što je prikazano u sekvenci SEQ ID NO: 387.
The first agent and the second agent for the use of any one of claims 1 to 3, wherein said first agent is an antibody, particularly a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a humanized antibody, a human antibody, a chimeric antibody, a multispecific antibody, or an antibody fragment thereof, particularly a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv fragment, a diabody, or a single chain antibody molecule, particularly an antibody of the IgG1-, IgG2-, IgG3- or IgG4- type. 
Prvo sredstvo i drugo sredstvo za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time što navedeni antigen-vezujući protein koji se veže za HER-3 predstavlja antitijelo, naročito monoklonsko antitijelo, poliklonsko antitijelo, rekombinirano antitijelo, humanizirano antitijelo, humano antitijelo, himerno antitijelo, multispecifično antitijelo, ili njihov fragment antitijela, naročito Fab fragment, Fab' fragment, F(ab')2 fragment, Fv fragment, di-antitijelo, ili molekula jednolančanog antitijela, naročito antitijelo tipa IgG1, IgG2, IgG3 ili IgG4.
The first agent and the second agent for the use of claim 1, wherein said first agent is coupled to an effector group, particularly to a radioisotope or radionuclide, a toxin, or a therapeutic or chemotherapeutic group, wherein the therapeutic or chemotherapeutic group is preferably calicheamicin, auristatinPE, geldanamycin, maytansine and derivatives thereof. 
Prvo sredstvo i drugo sredstvo za upotrebu prema patentnom zahtjevu 1, naznačeno time što je navedeno prvo sredstvo vezano za efektorsku grupu, naročito za radioizotop ili radionuklid, toksin, ili terapijsku ili kemoterapijsku grupu, gdje je terapijska ili kemoterapijska grupa poželjno kaliheamicin, auristatinPE, geldanamicin, maitansin i njihovi derivati.
The first agent and the second agent for the use of claim 1, said treatment or prevention comprising administering said first agent or second agent at a dose of about 1 to about 20 mg/kg body weight, at least once every 6 weeks. 
Prvo sredstvo i drugo sredstvo za upotrebu prema patentnom zahtjevu 1, navedeno liječenje ili prevencija sadrži primjenu navedenog prvog sredstva ili drugog sredstva u dozi od oko 1 do oko 20 mg/kg tjelesne težine, najmanje jednom svakih 6 tjedana.
The first agent and the second agent for the use of claim 1, said treatment or prevention further comprising, after the administration to a subject, monitoring the therapeutic outcome. 
Prvo sredstvo i drugo sredstvo za upotrebu prema patentnom zahtjevu 1, navedeno liječenje ili prevencija dalje sadrži, nakon primjene kod subjekta, praćenje terapijskog ishoda.
Awning structure according to Claim 1, characterized in that the front beam (5) comprises, on at least one of its ends, an end part (50) that is fastened to a vertical wall of a column (7), (8). 
Struktura cerade u skladu s patentnim zahtjevom 1, naznačena time što prednja greda (5) sadrži, na najmanje jednom od svojih krajeva, krajnji dio (50), koji je pričvršćen na okomitu stijenku stupca (7), (8).
Awning structure according to claim 7, characterized in that it comprises a closing plate (32) for closing said opening for the awning (31). 
Struktura cerade u skladu s patentnim zahtjevom 8, naznačena time što sadrži ploču za zatvaranje (32), namijenjenu zatvaranju navedenog otvora za ceradu (31).
Awning structure according to one of the preceding claims, characterized in that a strengthening element (38) is fastened to at least one of the walls (13b) of the front beam (5) extending in the longitudinal direction (A). 
Struktura cerade u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je element za ojačavanje (38), pričvršćen na najmanje jednu od stijenki (13b) prednje grede (5) koja se pruža u uzdužnom smjeru (A).
Awning structure according to claim 9, characterized in that the strengthening element (38) is fastened in the internal space (12) to a wall (13b) of the front beam (5). 
Struktura cerade u skladu s patentnim zahtjevom 10, naznačena time što je element za ojačavanje (38), pričvršćen u unutarnjem prostoru (12) na stijenku (13b) prednje grede (5).